4 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Trefoil Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation TTHX1114 Ophthalmic Solution TTHX1114(NM141) Ophthalmic Solution - Corneal Epithelial Degeneration | Phase 1 | Completed | Trefoil Therapeutics, Inc. | 8 | 2022-12-06 | 2023-04-18 |
| A Safety and Efficacy Trial of TTHX1114 in People With CED TTHX1114 - Corneal Endothelial Dystrophy | Phase 2 | Completed | Trefoil Therapeutics, Inc. | 41 | 2021-11-30 | 2023-11-07 |
| TTHX1114(NM141) in Combination With DWEK/DSO TTHX1114(NM141) - Fuchs' Endothelial Dystrophy, Fuchs Dystrophy | Phase 2 | Completed | Trefoil Therapeutics, Inc. | 49 | 2021-02-01 | 2023-11-07 |
| A Phase 1/ Phase 2 Study of TTHX1114(NM141) TTHX1114(NM141), Vehicle (placebo) - Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy | Phase 1 / Phase 2 | Completed | Trefoil Therapeutics, Inc. | 22 | 2020-08-19 | 2023-10-30 |
Corneal Dystrophy, Posterior Polymorphous, 1 (2) · Fuchs' Endothelial Dystrophy (2)
United States (4)
Thomas Tremblay (3) · Thomas M Tremblay, RN BSN (1)